Analysts See $-0.91 EPS for Sarepta Therapeutics (SRPT); Resolute Energy (REN) Had 10 Bullish Analysts

June 16, 2017 - By Vivian Park

Analysts expect Sarepta Therapeutics Inc (NASDAQ:SRPT) to report $-0.91 EPS on July, 18.They anticipate $0.43 EPS change or 32.09% from last quarter’s $-1.34 EPS. After having $-0.73 EPS previously, Sarepta Therapeutics Inc’s analysts see 24.66% EPS growth. The stock decreased 2.29% or $0.76 on June 15, reaching $32.38. About shares traded. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 96.82% since June 16, 2016 and is uptrending. It has outperformed by 80.12% the S&P500.

Among 13 analysts covering Resolute Energy (NYSE:REN), 10 have Buy rating, 0 Sell and 3 Hold. Therefore 77% are positive. Resolute Energy had 21 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Monday, July 11 by Northland Capital. The firm earned “Buy” rating on Monday, August 22 by Wunderlich. Northland Capital maintained the shares of REN in report on Wednesday, August 12 with “Market Perform” rating. The rating was initiated by KLR Group on Tuesday, December 6 with “Buy”. The firm has “Buy” rating by Wunderlich given on Thursday, October 6. On Monday, December 19 the stock rating was upgraded by CapitalOne to “Overweight”. Barclays Capital upgraded the shares of REN in report on Wednesday, July 13 to “Equal-Weight” rating. The rating was initiated by Seaport Global Securities on Wednesday, October 5 with “Buy”. As per Tuesday, June 14, the company rating was maintained by Barclays Capital. SunTrust maintained Resolute Energy Corp (NYSE:REN) on Wednesday, August 12 with “Neutral” rating. See Resolute Energy Corp (NYSE:REN) latest ratings:

01/06/2017 Broker: SunTrust Rating: Buy New Target: $55.00 Initiate
01/06/2017 Broker: Suntrust Robinson Rating: Buy Initiate
09/01/2017 Broker: BMO Capital Markets Rating: Outperform New Target: $50.00 Initiates Coverage On
19/12/2016 Broker: CapitalOne Old Rating: Equal Weight New Rating: Overweight Upgrade

The stock decreased 6.47% or $2.23 on June 15, reaching $32.23. About shares traded. Resolute Energy Corp (NYSE:REN) has risen 1441.16% since June 16, 2016 and is uptrending. It has outperformed by 1424.46% the S&P500.

Resolute Energy Corporation is an independent gas and oil company. The company has market cap of $676.26 million. The Firm is engaged in the exploitation, development, exploration for and acquisition of gas and oil properties. It currently has negative earnings. The Company’s assets are located primarily in the Delaware Basin in west Texas and Aneth Field located in the Paradox Basin in southeast Utah (the Aneth Field Properties or Aneth Field).

Investors sentiment decreased to 1.07 in 2016 Q4. Its down 0.45, from 1.52 in 2016Q3. It fall, as 42 investors sold Sarepta Therapeutics Inc shares while 46 reduced holdings. 39 funds opened positions while 55 raised stakes. 38.63 million shares or 7.09% less from 41.57 million shares in 2016Q3 were reported. Next Fin Group Incorporated invested in 1,000 shares or 0% of the stock. Glenmede Tru Communications Na stated it has 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). Jefferies Grp Ltd Liability holds 0.13% or 839,342 shares. Riggs Asset Managment stated it has 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). Wells Fargo Co Mn reported 0% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Jennison Associates Ltd Com holds 0.02% in Sarepta Therapeutics Inc (NASDAQ:SRPT) or 563,333 shares. Invesco Ltd owns 456,598 shares or 0% of their US portfolio. Voya Invest Management Llc has invested 0% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Price T Rowe Assocs Md, Maryland-based fund reported 381,173 shares. Moreover, Great West Life Assurance Company Can has 0% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 4,935 shares. Prelude Cap Mgmt, New York-based fund reported 3,724 shares. Tekla Capital Mgmt holds 466,300 shares. Morgan Stanley invested 0% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Moreover, Macquarie Group Limited has 0% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT). Spark Ltd Liability has 0.08% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 36,000 shares.

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The company has market cap of $1.74 billion. The Firm focuses on the discovery and development of ribose nucleic acid -targeted therapeutics for the treatment of rare neuromuscular diseases. It currently has negative earnings. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Among 24 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 16 have Buy rating, 1 Sell and 7 Hold. Therefore 67% are positive. Sarepta Therapeutics had 62 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) has “Sector Perform” rating given on Tuesday, January 19 by RBC Capital Markets. On Monday, September 19 the stock rating was maintained by Robert W. Baird with “Outperform”. The rating was downgraded by Piper Jaffray on Friday, January 15 to “Neutral”. The firm has “Perform” rating by Oppenheimer given on Tuesday, April 26. The firm has “Outperform” rating given on Wednesday, July 20 by Wedbush. William Blair maintained Sarepta Therapeutics Inc (NASDAQ:SRPT) on Wednesday, August 26 with “Buy” rating. On Monday, September 19 the stock rating was upgraded by Jefferies to “Hold”. The firm earned “Hold” rating on Friday, October 23 by Jefferies. The rating was downgraded by William Blair on Thursday, April 21 to “Market Perform”. As per Wednesday, September 28, the company rating was maintained by RBC Capital Markets.